Cardiotoxicity from cancer treatment
Cardiotoxicity from cancer treatment means damage to the heart or its function caused by cancer treatments such as chemotherapy, immunotherapy or radiation. A 2025 review says these treatments have increased survival but are frequently linked to cardiovascular toxicity, which has a significant impact on outcomes and well-being. The review says the changes can lead to conditions such as cardiomyopathy and can result in heart failure and sudden cardiac death.
Also called Cancer therapy-related cardiovascular toxicity · Cardiotoxicity
- Condition
- In this atlas
Overview
Technical summary
MeSH Cardiotoxicity (D066126) is recorded as a broad match: its scope note covers damage to the heart from toxic substances, including chemotherapy, immunotherapy and radiation, and is not limited to cancer care. The description rests on that scope note and on a 2025 review under a CC BY licence (Heart Failure Reviews). The review says there is no universally accepted definition and that the condition is often defined clinically as a reduction in left ventricular ejection fraction. Drug names, risk factors, monitoring and protective strategies in the review are not repeated here. The evidence is descriptive and comes from a narrative review, with no trial data.
Classification codes
-
D066126
Burden
No burden claims are published.
Claims and evidence
Context People treated for cancer with chemotherapy, targeted therapy, immunotherapy or radiotherapy (narrative review)
- Recipient
- Recipient not specified
- Population
- People who have had cancer treatment such as chemotherapy, targeted therapy, immunotherapy or radiotherapy, as the review describes them. The review also mentions long-term studies of childhood cancer survivors.
- Care setting
- Cancer treatment and cardio-oncology care, as described in the review.
- Geography
- Not stated for the review as a whole.
- Life stage
- Adults and children are not separated here. This record makes no statement about pregnancy, newborns or children.
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (a description of a condition).
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Having had cancer treatment that can harm the heart
- Excluded
- None stated
MeSH describes cardiotoxicity as damage to the heart or its function after exposure to toxic substances such as chemotherapy drugs, immunotherapy or radiation. A 2025 narrative review (Heart Failure Reviews) says cancer treatments are frequently linked to cardiovascular toxicity with a significant impact on clinical outcomes and well-being, that there is no universally accepted definition of the condition (it is often defined clinically as a reduction in left ventricular ejection fraction), and that the changes can lead to dilated and restrictive cardiomyopathy and can result in heart failure and sudden cardiac death.
Applies to Recipient not specified People treated for cancer with chemotherapy, targeted therapy, immunotherapy or radiotherapy (narrative review)
- Certainty method
- Not assessed
- Limitations
- A narrative review and a thesaurus scope note, not a study of how often the damage occurs. The MeSH descriptor is not limited to cancer care. The review gives no risk figures here: its drug names, mechanisms, risk estimates, classification, monitoring and protective strategies are not repeated, and nothing here says who should be monitored or how.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (7)
-
Supports MeSH scope note for descriptor D066126 (Cardiotoxicity)
- Locator
- scopeNote.@value, sentence 1
- How it applies
- MeSH scope note: heart damage from chemotherapy, immunotherapy or radiation.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
f80e554a493c601a68a23f9ff8b6f60bc0310dc074bd769961c0d895b865f807- Reuse basis
- The NLM web policies page (sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. The NLM MeSH terms and conditions page (sha256 f33b14141a5b6c8a2b1464c751dbdbb0a0d476c913851bf2a8c3d5c14b1afce7, hash only) asks redistributors to maintain current data or to make known that their copy may not reflect the most current data. This copy was fetched on 2026-11-18 and may not reflect the most current data. The raw bytes are committed in the atlas repository.
-
Supports Cancer therapy-induced cardiotoxicity: mechanisms and mitigations
- Locator
- Abstract, sentence 2
- How it applies
- Cancer treatments are frequently linked to cardiovascular toxicity.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution 4.0 licence (https://creativecommons.org/licenses/by/4.0/). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
Supports Cancer therapy-induced cardiotoxicity: mechanisms and mitigations
- Locator
- Introduction, para 2, sentence 2 (first part)
- How it applies
- No universally accepted definition.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution 4.0 licence (https://creativecommons.org/licenses/by/4.0/). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
Supports Cancer therapy-induced cardiotoxicity: mechanisms and mitigations
- Locator
- Introduction, para 2, sentence 2 (second part)
- How it applies
- Often defined clinically as a fall in ejection fraction.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution 4.0 licence (https://creativecommons.org/licenses/by/4.0/). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
Supports Cancer therapy-induced cardiotoxicity: mechanisms and mitigations
- Locator
- Abstract, sentence 5 (first part)
- How it applies
- The changes can lead to cardiomyopathy.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution 4.0 licence (https://creativecommons.org/licenses/by/4.0/). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
Supports Cancer therapy-induced cardiotoxicity: mechanisms and mitigations
- Locator
- Abstract, sentence 5 (end)
- How it applies
- The conditions can result in heart failure and sudden cardiac death.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution 4.0 licence (https://creativecommons.org/licenses/by/4.0/). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
Background Cancer therapy-induced cardiotoxicity: mechanisms and mitigations
- Locator
- Abstract, sentence 1
- How it applies
- Context: the treatments have increased survival.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution 4.0 licence (https://creativecommons.org/licenses/by/4.0/). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact A 2025 review says cancer treatment-related heart changes can lead to dilated and restrictive cardiomyopathy: Cardiomyopathy (heart muscle disease)
Applies to Recipient not specified People treated for cancer with chemotherapy, targeted therapy, immunotherapy or radiotherapy (narrative review)
MeSH describes cardiotoxicity as damage to the heart or its function after exposure to toxic substances such as chemotherapy drugs, immunotherapy or radiation. A 2025 narrative review (Heart Failure Reviews) says cancer treatments are frequently linked to cardiovascular toxicity with a significant impact on clinical outcomes and well-being, that there is no universally accepted definition of the condition (it is often defined clinically as a reduction in left ventricular ejection fraction), and that the changes can lead to dilated and restrictive cardiomyopathy and can result in heart failure and sudden cardiac death.Limitations. A narrative review and a thesaurus scope note, not a study of how often the damage occurs. The MeSH descriptor is not limited to cancer care. The review gives no risk figures here: its drug names, mechanisms, risk estimates, classification, monitoring and protective strategies are not repeated, and nothing here says who should be monitored or how.
-
Claim, not a settled fact A 2025 review says the conditions that follow can result in heart failure: Heart failure
Applies to Recipient not specified People treated for cancer with chemotherapy, targeted therapy, immunotherapy or radiotherapy (narrative review)
MeSH describes cardiotoxicity as damage to the heart or its function after exposure to toxic substances such as chemotherapy drugs, immunotherapy or radiation. A 2025 narrative review (Heart Failure Reviews) says cancer treatments are frequently linked to cardiovascular toxicity with a significant impact on clinical outcomes and well-being, that there is no universally accepted definition of the condition (it is often defined clinically as a reduction in left ventricular ejection fraction), and that the changes can lead to dilated and restrictive cardiomyopathy and can result in heart failure and sudden cardiac death.Limitations. A narrative review and a thesaurus scope note, not a study of how often the damage occurs. The MeSH descriptor is not limited to cancer care. The review gives no risk figures here: its drug names, mechanisms, risk estimates, classification, monitoring and protective strategies are not repeated, and nothing here says who should be monitored or how.
Record details
- Record id
cardio:cardiotoxicity-from-cancer-treatment- Content hash
236dbd27bff0068450a0e51859dfce956504cc6ac0bad57b5871f6434113cb8e